Acquisition foothold Leverage potential integration with Philips' vascular devices portfolio post-acquisition to expand distribution, co-marketing, and cross-sell opportunities in deep venous disease devices.

Private growth ploys Target strategic financing and partnerships to accelerate product development and clinical trials, using the company’s existing $37M funding history to engage growth-oriented investors and OEM collaborators.

Clinical leadership Engage with the board and CMO to identify key opinion leaders and trial sites for expanding the VIVID trial footprint or new evaluative studies in iliac and femoral venous disease.

SME to enterprise Position Vesper’s modular venous stent portfolio as a scalable solution for mid-market hospital networks seeking customizable venous interventions, with emphasis on outcomes, reuse, and ease of adoption.

Global expansion Explore international distribution and strategic partnerships to extend reach beyond the US, leveraging Philips’ global footprint and Vesper’s specialized venous stents to capture emerging markets and add-ons to existing vascular portfolios.